Defining Predictors of Weight Loss Response to Lorcaserin
Authors' conclusion
Our results provide evidence that LOR affects the brain melanocortin system in humans and that effectiveness is increased in individuals with lower melanocortin activity. Furthermore, early changes in CSF POMC parallel WL-independent improvements in glycemic indexes. Thus, assessment of melanocortin activity could provide a way to personalize pharmacotherapy of obesity with 5HT2cR agonists.
Study context
- Population
- Individuals with obesity19 continued lorcaserin (LOR) 6 months
- Participants
- 30 individuals
- Comparison
- Lorcaserin vs placebo
Methodological detailsrandomized crossover, 7 days placebo and LOR, 6-month LOR continuation
- Randomized crossover
- 7 days placebo and LOR
- 6-month LOR continuation
Primary result
As reported in the abstract
CSF POMC peptides after 7 days of LOR
β-endorphin/proopiomelanocortin (POMC) increase
30%
P < .001
Further findings
Insulin, glucose and HOMA-IR · 7 days, before weight loss (WL)
- Substantial decrease in insulin, glucose and HOMA-IR before WL
Cerebrospinal fluid (CSF) POMC peptides after 6 months of LOR
- WL
- 6.9%
- Changes in CSF POMC peptides persisted after WL, distinct from prior reports after diet alone
Predictors of WL · 6 months
- Baseline CSF POMC correlated negatively with WL
- P = 0.07
- Changes in POMC, food intake or other hormones did not predict WL
- A cutoff level of CSF POMC predicted >10% WL
Original publication
Defining Predictors of Weight Loss Response to Lorcaserin. J Clin Endocrinol Metab. Published 10 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →